Nirmatrelvir is the main component of Paxlovid, an oral antiviral drug approved for the
treatment of COVID-19 caused by SARS-COV-2 infection. Nirmatrelvir targets the main …

The COVID-19 pandemic continues to be a public health threat with emerging variants of
SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the …

The US FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has
significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an …

Abstract SARS-CoV-2 main protease (M pro) is a validated antiviral drug target of
nirmatrelvir, the active ingredient in Pfizer's oral drug Paxlovid. Drug-drug interactions limit …

The COVID-19 pandemic continues to be a public health threat with emerging variants of
SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the …

Abstract On December 22, 2021, the United States Food and Drug Administration approved
the first main protease inhibitor, ie, oral antiviral nirmatrelvir (PF-07321332)/ritonavir …

SARS-CoV-2 continues to pose a threat to public health. Main protease (Mpro) is one of the
most lucrative drug targets for developing specific antivirals against SARS-CoV-2 infection …

Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …

Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main
protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related …

Nirmatrelvir is an orally available inhibitor of SARS-CoV-2 main protease (Mpro) and the
main ingredient of PAXLOVID, a drug approved by FDA for high-risk COVID-19 patients …